I honestly believe there’s a legitimate concern that because the company is limited to 1.2 million doses this year to announce the approval of a drug with remarkable results that’s limited to 200,000 patients will ignite a debate of privilege along lines of race wealth socioeconomic lines the likes of which the country is not prepared..Who decides which patients live in which die?
News 
Market Data 
Discover 
